2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
Business Wire•20/10/2026•16:00 ET
0
Key Highlights
- ➤ADA/EASD recommends hypercortisolism screening for treatment-resistant type 2 diabetes
- ➤CATALYST found hypercortisolism in 24% of 1,057 difficult-to-control diabetes patients
- ➤Mifepristone reduced HbA1c 1.47% versus 0.15% with placebo over 24 weeks
- ➤Report says cortisol-directed mifepristone therapy may benefit hyperglycemia management
- ➤Screening studies identify a treatable cause in approximately 25% of cases
Expert Statements
John B. Buse, Professor of Medicine, University of North Carolina School of Medicine, and co-chair of the ADA/EASD consensus report writing group
“Evidence continues to mount that patients whose hyperglycemia does not respond to standard-of-care medications should be screened for hypercortisolism. Excess cortisol can contribute to cardiometabolic disease, including type 2 diabetes and high blood pressure, and cortisol-directed therapy may benefit these patients.”
Bill Guyer, Chief Development Officer, Corcept Therapeutics
“There is an urgent need for improved screening for and treatment of hypercortisolism. The findings from our CATALYST study are an important advance in the understanding of this disease. We are heartened that ADA and EASD have recognized this practice-changing research and now recommend that physicians screen patients for hypercortisolism-induced hyperglycemia.”
2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
Joint recommendation cites Corcept’s CATALYST study on the prevalence and treatment of hypercortisolism in patients whose blood sugar remains high despite use of multiple glucose-lowering medications
Get started
Create a free account to read the full story.